A 1.5 hour webinar delivered by experts providing an overview of the following topics: Mechanisms of viral evolution and evasion. Evolutionary pressures. Immune evasion measures differences and similarities between RIDs (including mutation rates etc.). Effects of vaccination/non-vaccination. Predicting viral evolution and future-proofing vaccines and therapeutics against viral resistance. Viral surveillance and monitoring. How to implement a system to monitor viral evolution. The webinar includes an interactive Q&A session with the experts.
At BioNTech we understand that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized.
To pioneer the next generation of patient-specific immunotherapies, we have combined ground-breaking research with cutting-edge technologies to develop therapeutics for cancer and beyond. Our broad and synergistic suite of platforms, which include mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators have been optimized for distinct modes of action, high precision targeting, high potency and efficacy. We are also developing in parallel our own state-of-the-art manufacturing processes to complement our drug development platforms.
